family-medicine-2017-keynote

Page 14

Notes:

Arch Gen Intern Med 2017 | Volume 1 Issue 3

allied

academies

International Conference on

FAMILY MEDICINE AND FAMILY PHYSICIANS

October 16-17, 2017 | Toronto, Canada

headventofautomatedhumangeneticsequencingcapability

has allowed a crossover for sequencing infectious diseases.

The same technologies that allow us to query the human

genome for cancer mutations, SNP’s, pharmacogenomics,

and inborn genetic errors now allow more in-depth analysis

of human samples for evidence of infectious disease. Next -

Generation sequencing (NGS) for infectious disease has proven

to be more accurate with greater sensitivity and specificity

than culture, serologic and PCR methods. They also now allow

better discrimination of species, detection of novel variants,

new novel organisms, detection of an ever-growing array of

uncultivable organisms, and the ability to detect eukaryotes

that before were undetectable. NGS also may soon hold the

ability to additionally provide drug resistance and sensitivity

information. Here we describe the rapid infectious disease

identification system, RIDI™, and its practical use. Application

of the RIDI™ system is discussed in four case reports with

patients suffering from chronic malaise, rheumatoid arthritis,

osteoarthritis, and chronic fatigue syndrome with discussion

providing new insight..

Speaker Biography

Stephen E Fry has completed a BS inMicrobiology, MS inMolecular Biology andMedical

Degree all earned at the University of Arizona. He completed his Post-graduate training

at Banner Health and St. Joseph’s Medical Center in the Phoenix metropolitan area. He

has been in general practice in the Scottsdale, Arizona since 1992 and has had a special

clinical interest in CFS, autoimmune and vascular disease. He has lectured nationally

and has numerous publications, abstracts, and patents. His science interests are in the

microbial causation of chronic disease, biofilms, and their treatment. Because of these

interests he has worked on new methods for disease detection which have culminated

in the development of a next-gen sequencing system for microbial identification.

He is the Founder of Fry Laboratories LLC, a CLIA clinical diagnostic laboratory that

participates in CAP and API validation systems. The laboratory specializes in the vector

borne diseases, molecular methods of detection of prokaryotes, archaea, protozoans,

and fungi.

Stephen E Fry

Fry Laboratories, USA

Applied use of next gen sequencing for infectious disease